ライフサイエンスコーパス: programmed death

1 required to protect cells from commitment to programmed death.

2 pathways, and report that high expression of programmed death 1 (PD-1(hi)) marked a committed ILC pro

3 s, the molecular mechanism for regulation of programmed death 1 (PD-1) and its ligand (PD-L1) is part

4 Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-

5 8(+) T cells in BAL had higher expression of programmed death 1 (PD-1) and lower cytotoxic T-lymphocy

6 munoinhibitory receptors on T cells, such as programmed death 1 (PD-1) and lymphocyte activation gene

7 We focused on Programmed Death 1 (PD-1) and T cell Ig- and mucin-domai

8 ly recognized consequence of the use of anti-programmed death 1 (PD-1) antibodies in the treatment of

9 lantation (post-allo-HCT) and the success of programmed death 1 (PD-1) blockade in classical Hodgkin

10 the impressive rates of clinical response to programmed death 1 (PD-1) blockade in multiple cancers,

11 V-1), CD8alpha(+) dendritic cells (DCs), and programmed death 1 (PD-1) have all been implicated in th

12 Blocking the programmed death 1 (PD-1) immune inhibitory pathway is o

13 Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor an

14 and safety of nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor an

15 Response to programmed death 1 (PD-1) inhibitors has been associated

16 Programmed death 1 (PD-1) is a potent inhibitor of T cel

17 Programmed death 1 (PD-1) is an immunologic checkpoint t

18 High surface expression of programmed death 1 (PD-1) is associated with T-cell exha

19 ated with significantly higher expression of programmed death 1 (PD-1) on CD4 T cells.

20 Expression of programmed death 1 (PD-1) on CD8 T cells promotes T cell

21 ell-surface glycoproteins that interact with programmed death 1 (PD-1) on T cells to attenuate inflam

22 Preclinical studies suggest that programmed death 1 (PD-1) pathway is critical to inhibit

23 The programmed death 1 (PD-1) pathway limits immune response

24 uggest that Reed-Sternberg cells exploit the programmed death 1 (PD-1) pathway to evade immune detect

25 ways, such as the interleukin-10 (IL-10) and programmed death 1 (PD-1) pathways, as a therapy to cure

26 Programmed death 1 (PD-1) receptor and its ligand (PD-L1

27 Expression of the programmed death 1 (PD-1) receptor and its ligands are i

28 Overexpression of programmed death 1 (PD-1) receptor is thought to inhibit

29 expressed levels of the inhibitory receptor programmed death 1 (PD-1) similar to those of WT mice.

30 esponsive to immune checkpoint blockade with programmed death 1 (PD-1) targeted agents, novel immunot

31 oximately 75% of objective responses to anti-programmed death 1 (PD-1) therapy in patients with melan

32 ma and toward IL-17 through interaction with programmed death 1 (PD-1), an effect that can create fav

33 Interaction between PD-L1 and its receptor, programmed death 1 (PD-1), inhibits the function of acti

34 ytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1), is being targeted for cancer

35 sponse and outcome after treatment with anti-programmed death 1 (PD-1).

36 CD8(+) T cell (TCD8) impairment, mediated by programmed death 1 (PD-1).

37 CD8(+) T cell (TCD8) impairment mediated by programmed death 1 (PD-1).

38 itumour activity of antibodies targeting the programmed death 1 (PD-1): programmed death ligand 1 (PD

39 Programmed death 1 (PD1) is a negative regulator of T ce

40 f inhibitory costimulatory pathways, such as programmed death 1 (PD1)/programmed death ligand 1, lead

41 Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipil

42 ells (MDSC), and exhausted T effector cells (programmed death 1 [PD-1](+)) in patients with COPD, bec

43 atients treated with nivolumab received anti-programmed death 1 agents after randomly assigned therap

44 i-programmed death ligand 1 (PD-L1) and anti-programmed death 1 agents has expanded treatment options

45 alpha-GalCer-triggered egr2/3, which induced programmed death 1 and cbl-b in NKT cells, leading to NK

46 also correlated with therapeutic efficacy of programmed death 1 and PD-L1 inhibitors.

47 production, CD4(+) T cells exhibit increased programmed death 1 and T cell Ig mucin-like domain 3 exp

48 onding to immune-checkpoint blockade by anti-programmed death 1 antibodies (anti-PD1).

49 Regulatory BMDC require IL-10 and programmed death 1 as well as downregulation of CD40 and

50 Viral suppression reduced Fas receptor and programmed death 1 expression in lung CD4(+) T cells, co

51 Nivolumab, a fully human immunoglobulin G4 programmed death 1 immune checkpoint inhibitor antibody,

52 clinical activity of pembrolizumab, an anti-programmed death 1 immune checkpoint inhibitor, in 41 pa

53 elected to enroll onto a clinical trial of a programmed death 1 inhibitor.

54 s associated with a higher expression of the programmed death 1 inhibitory receptor, and blockade of

55 Programmed death 1 is an immune checkpoint that suppress

56 , such as programmed death ligand 1 (PD-L1), programmed death 1 ligand 2 (PD-L2), and the butyrophili

57 , and granzyme B and decreased expression of programmed death 1 on these cells.

58 ld only partly be rescued by blockade of the programmed death 1 pathway.

59 T cells express high levels of the receptor programmed death 1 protein (PD-1), while those from dise

60 ere associated with marked expression of the programmed death 1 protein (PD-1).

61 5 study, we evaluated pembrolizumab, an anti-programmed death 1 receptor antibody, in this platinum-

62 e both populations expressing high levels of programmed death 1 receptor.

63 e to Ag-specific stimulation, and upregulate programmed death 1 receptor.

64 y expression of inhibitory receptors such as programmed death 1 that limit persistent inflammation.

65 sed expression of the coinhibitory receptor, programmed death 1, resulting in Ag-specific T cells tha

66 s shown to be dampened by IL-10 and eventual programmed death 1-mediated T cell exhaustion.

67 that binds to the T-cell immune check point programmed death 1.

68 Immunotherapeutic approaches, particularly programmed death 1/programmed death ligand 1 (PD-1/PD-L1

69 their arg-1 mRNAs and enhanced expression of programmed death 1/programmed death ligand 1.

70 otoxic T-lymphocyte associated protein 4 and programmed-death 1 (PD-1), has become a paradigm-shiftin

71 After immunization, programmed death -1 (PD-1)(high) T(FH) cells in Bcl6(fl/

72 f specific TCR Vbeta subtypes, the impact of programmed death -1 (PD-1), CTL-associated protein 4 (CT

73 -reactive T cells by binding to its receptor programmed death-1 (CD279), renders tumor cells resistan

74 cking the 'cancer immunity cycle' by binding programmed death-1 (PD-1) and B7.1 (CD80), both of which

75 p-regulation of inhibitor receptors, such as programmed death-1 (PD-1) and its ligand, PD-L1, are imp

76 The interactions between programmed death-1 (PD-1) and its ligands hamper tumor-s

77 monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-1) and PD-L1 and B7-1 interaction

78 rammed death ligand-1 (PD-L1) interacts with programmed death-1 (PD-1) and the immunostimulatory mole

79 ), lymphocyte activation gene-3 (LAG-3), and programmed death-1 (PD-1) are involved in the functional

80 Blocking Programmed Death-1 (PD-1) can reinvigorate exhausted CD8

81 The inhibitory receptor programmed death-1 (PD-1) constrains type 1 diabetes (T1

82 tigen recognition led to upregulation of the programmed death-1 (PD-1) glycoprotein by T cells and bl

83 The inhibitory receptor programmed death-1 (PD-1) has been shown to regulate CD8

84 Programmed Death-1 (PD-1) has received considerable atte

85 of T cell activation such as CD69, CD44, and programmed death-1 (PD-1) have been used.

86 Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor an

87 Cancer cells can exploit the programmed death-1 (PD-1) immune checkpoint pathway to a

88 or radiotherapy (hRT) and/or blockade of the programmed death-1 (PD-1) immune checkpoint, both of whi

89 lls (MDSCs), regulatory T cells (Tregs), and programmed death-1 (PD-1) inhibitory molecule expression

90 Programmed death-1 (PD-1) is a crucial negative regulato

91 Expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) is used to se

92 Cancer cells exploit the expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) to subvert T-

93 alterations leading to overexpression of the programmed death-1 (PD-1) ligands, suggesting a possible

94 The coinhibitory receptor programmed death-1 (PD-1) maintains immune homeostasis b

95 osis is associated with higher expression of programmed death-1 (PD-1) on gB-Tet(-) CD8(+) T cells an

96 Blockade of programmed death-1 (PD-1) on the surface of Tregs, prior

97 functions, revealed a critical role for the programmed death-1 (PD-1) pathway in CAR T cell exhausti

98 Programmed death-1 (PD-1) promotes T cell tolerance.

99 Therapies that target the programmed death-1 (PD-1) receptor have shown unpreceden

100 -1 (PD-L1) concurrent with enrichment of the programmed death-1 (PD-1) receptor.

101 ted production of interleukin 10 (IL-10) and programmed death-1 (PD-1) the dominant negative regulato

102 Plasmodium spp., exploit the interaction of programmed death-1 (PD-1) with PD-1-ligand-1 (PD-L1) to

103 Pretreatment levels of programmed death-1 (PD-1)+ peripheral blood T cells (PD-

104 urface expression of the inhibitory receptor programmed death-1 (PD-1), but surprisingly, while the i

105 lymphocyte associated antigen-4 (CTLA-4) and programmed death-1 (PD-1), two immunomodulatory receptor

106 g antitumor adaptive T cell immunity via the programmed death-1 (PD-1)-programmed death ligand-1 (PD-

107 iratory infection by the inhibitory receptor programmed death-1 (PD-1).

108 study, we studied cTfh expressing CXCR5 and programmed death-1 (PD-1).

109 ptor gamma t and IFN regulator factor-4 in a programmed death-1 and B7-independent fashion.

110 tory T cells and CD4(+) T-cell expression of programmed death-1 and cytotoxic T lymphocyte-associated

111 sEPD of anti-programmed death-1 antibody showed more potent anti-tumo

112 Purpose The addition of nivolumab (anti-programmed death-1 antibody) to ipilimumab (anti-cytotox

113 The efficacy and safety of nivolumab (a programmed death-1 checkpoint inhibitor), alone or combi

114 odulatory anticancer drugs, such as the anti-programmed death-1 drug pembrolizumab, have shown promis

115 eath ligand 1 that, through interaction with programmed death-1 expressed on DCs, limited DC activati

116 However, programmed death-1 expression inversely correlated with

117 ivation (VISTA), and the other used the term programmed death-1 homolog (PD-1H).

118 Programmed death-1 homolog (PD-1H, also called VISTA) is

119 Nivolumab is a fully human immunoglobulin G4 programmed death-1 immune checkpoint inhibitor antibody

120 Nivolumab, a fully human immunoglobulin G4 programmed death-1 immune checkpoint inhibitor antibody,

121 with recurrent multifocal GBM with the anti-programmed death-1 inhibitor nivolumab, which resulted i

122 Purpose Nivolumab, a programmed death-1 inhibitor, prolonged overall survival

123 Blockade of the programmed death-1 inhibitory cell-surface molecule on i

124 Expression of PD-L1 and programmed death-1 is elevated in the salivary glands of

125 novel molecules heme oxygenase-1 (HO-1) and programmed death-1 ligand 1 (PD-L1).

126 interacts with the constitutively expressed programmed death-1 on the target T cells and stimulates

127 ked to reduced expression of 2B4, LAG-3, and programmed death-1 on tumor-infiltrating MAA-specific CD

128 ts were equally pronounced in the absence of programmed death-1 or B7.1 and B7.2 on the T cell side,

129 Although in vitro blockade of programmed death-1 or cytotoxic T lymphocyte-associated

130 and associated to an increased expression of Programmed Death-1 protein and CD57 on T cells, molecule

131 mab are monoclonal antibodies that block the programmed death-1 receptor (PD-1, CD279), resulting in

132 cytotoxic T lymphocyte antigen-4 (CTLA4) or programmed death-1 receptor/ligand (PD-1/PD-L1) improve

133 his is the largest analysis of data for anti-programmed death-1 therapy in mucosal melanoma to date.

134 Here, we report that programmed death-1(high) (PD-1(high)) tumor antigen (TA)

135 ased expression of inhibitory molecule PD-1 (Programmed Death-1) causes reactivation of latent diseas

136 cell coinhibitory receptors CTLA-4 and PD-1 (programmed death-1) that have shown activity in several

137 cell expression of regulatory markers FOXP3, programmed death-1, and cytotoxic T lymphocyte-associate

138 f IFN-gamma and IL-7R, reduced expression of programmed death-1, and decreased apoptosis.

139 ymphoma 6 (Bcl-6), CXC chemokine receptor 5, programmed death-1, and other Tfh-associated markers.

140 reased surface Fas death receptor (CD95) and programmed death-1, but similar bronchoalveolar lavage v

141 Programmed death-1, CTLA4, and TIM-3 displayed discrete

142 is correlated with impaired upregulation of programmed death-1, Egr2, and Grail.

143 ther endogenous IFN-gamma, such as CXCR3 and programmed death-1, or systematic IFN-gamma, such as NKG

144 Programmed death-1-directed (PD-1-directed) immune check

145 Here, we investigated whether programmed death-1-mediated (PD-1-mediated) T cell exhau

146 ase 2 phosphatase to the cytoplasmic tail of programmed death-1.

147 T cells, as well as immune checkpoints like programmed death-1.

148 onses by engaging the co-inhibitory receptor programmed death-1.

149 g blocking antibodies inhibiting PD-1/PD-L1 (programmed death-1/programmed death ligand 1) interactio

150 as been made toward our understanding of the programmed death-1/programmed death ligand-1 (PD-1/PD-L1

151 Signaling through programmed death-1/programmed death ligand-1 (PD-1/PD-L1

152 Programmed death and shedding of epithelial cells is a p

153 n increase in IL-10 and higher expression of programmed death ligand (PD-L)1 and PD-L2 - which were p

154 Costimulatory molecules, such as the programmed death ligand (PD-L1), might exert differentia

155 situ hybridization here, we report that the programmed death ligand (PDL) locus (9p24.1) is frequent

156 dies against programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) and cytotoxic T l

157 approaches, particularly programmed death 1/programmed death ligand 1 (PD-1/PD-L1) blockade, have im

158 h coinhibitory checkpoint blockade with anti-programmed death ligand 1 (PD-L1) Ab can restore functio

159 The approval of anti-programmed death ligand 1 (PD-L1) and anti-programmed de

160 We examined the expression of Programmed Death Ligand 1 (PD-L1) and defined the tumor

161 These cells also express programmed death ligand 1 (PD-L1) and interleukin-10, an

162 Blocking the interaction between Programmed Death Ligand 1 (PD-L1) and its receptor, PD-1

163 ntibodies that block the interaction between programmed death ligand 1 (PD-L1) and PD-1 have shown im

164 The anti-programmed death ligand 1 (PD-L1) antibody atezolizumab

165 ed patients and in subgroups on the basis of programmed death ligand 1 (PD-L1) expression and human p

166 1 (PD-1) inhibitors has been associated with programmed death ligand 1 (PD-L1) expression levels in s

167 Here we show that programmed death ligand 1 (PD-L1) expression on tumor ce

168 eg, EGFR/ALK /ROS1), if the patient has high programmed death ligand 1 (PD-L1) expression, pembrolizu

169 g cell subset that required interaction with programmed death ligand 1 (PD-L1) for development.

170 ies targeting the programmed death 1 (PD-1): programmed death ligand 1 (PD-L1) immune checkpoint in l

171 omparing programmed cell death protein 1 and programmed death ligand 1 (PD-L1) inhibitors to docetaxe

172 Programmed death ligand 1 (PD-L1) is an immune regulator

173 Programmed death ligand 1 (PD-L1) is expressed on a numb

174 own; however, virus-induced dysregulation of programmed death ligand 1 (PD-L1) may play a role.

175 Randomization was stratified according to programmed death ligand 1 (PD-L1) status, BRAF mutation

176 ever, despite lower expression of inhibitory programmed death ligand 1 (PD-L1), HMPV-specific CD8(+)

177 onoclonal antibody that binds selectively to programmed death ligand 1 (PD-L1), in this patient popul

178 ive regulators of T-cell activation, such as programmed death ligand 1 (PD-L1), programmed death 1 li

179 es that express IgA, interleukin (IL)-10 and programmed death ligand 1 (PD-L1), the appearance of whi

180 on the interaction with the B7 family member programmed death ligand 1 (PD-L1), which is substantiall

181 nivolumab with chemotherapy in patients with programmed death ligand 1 (PD-L1)-positive NSCLC.

182 cluding head and neck cancers (HNC), express programmed death ligand 1 (PD-L1).

183 ng subgroups defined by status regarding the programmed death ligand 1 (PD-L1).

184 ex vivo-matured and fetal liver HSCs express programmed death ligand 1 (PD-L1).

185 Recently, agents targeting the programmed death ligand 1 (PD-L1)/programmed death recep

186 Programmed death ligand 1 (PD-L1, also known as B7 homol

187 t blockade therapy with anti-CTLA-4 and anti-programmed death ligand 1 Abs, even when checkpoint bloc

188 Blocking the programmed death ligand 1 binding site just before i.v.

189 P3C stimulation did not induce programmed death ligand 1 expression on LSECs, thereby f

190 intermediate/proinflammatory, and increased programmed death ligand 1 expression on natural killer c

191 Finally, programed death protein 1/programmed death ligand 1 signaling pathways were essent

192 ulated expression of the inhibitory molecule programmed death ligand 1 that, through interaction with

193 y, these GC Tfh cells consistently expressed programmed death ligand 1 upon activation.

194 an up-regulation of OX40 ligand (OX40L) and programmed death ligand 1(PD-L1) expression.

195 PD-L1 (programmed death ligand 1) and PD-L2 are cell-surface gl

196 es inhibiting PD-1/PD-L1 (programmed death-1/programmed death ligand 1) interactions-is showing impre

197 (anti-cytotoxic T-lymphocyte antigen 4, anti-programmed death ligand 1) or proinflammatory cytokines

198 y pathways, such as programmed death 1 (PD1)/programmed death ligand 1, leading to T cell exhaustion

199 Conclusion In patients with programmed death ligand 1-positive advanced cervical can

200 e safety and efficacy of pembrolizumab in 20 programmed death ligand 1-positive, advanced solid tumor

201 markers human leukocyte antigen class II and programmed death ligand 1.

202 lar GzmB reduces Treg expression of CD39 and programmed death ligand 1.

203 nd enhanced expression of programmed death 1/programmed death ligand 1.

204 erate functional FOXP3(+) Treg cells through programmed death ligand 1.

205 We report that programmed death ligand 2 (PD-L2), a known ligand of PD-

206 oth Th2-promoting IFN regulatory factor 4(+) programmed death ligand 2(+) dendritic cells and ILT3(+)

207 D11c(int)MHCII(hi) DC revealed expression of programmed death ligand 2, CD301b, IFN regulatory factor

208 iators, including IL-10, TGF-beta1, IDO, and programmed death ligand 2, T. cruzi infection induced an

209 ored by antibody-mediated disruption of PD-1/programmed death ligand interaction.

210 our understanding of the programmed death-1/programmed death ligand-1 (PD-1/PD-L1) pathway (referred

211 Signaling through programmed death-1/programmed death ligand-1 (PD-1/PD-L1), but not through

212 Signaling via programmed death ligand-1 (PD-L1) and PD-L2 is crucial f

213 Extracellular interaction between programmed death ligand-1 (PD-L1) and programmed cell de

214 Programmed cell death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) checkpoint blockade ha

215 ed low expression of the coinhibitory ligand programmed death ligand-1 (PD-L1) concurrent with enrich

216 ggest that IFN-gamma is a critical driver of programmed death ligand-1 (PD-L1) expression in cancer a

217 Programmed death ligand-1 (PD-L1) interaction with PD-1

218 Programmed death ligand-1 (PD-L1) interacts with program

219 Programmed death ligand-1 (PD-L1) is a critical regulato

220 l immunity via the programmed death-1 (PD-1)-programmed death ligand-1 (PD-L1) pathway.

221 macrophage population exhibiting the markers programmed death ligand-1 (PD-L1), Mac-2, and macrophage

222 xpression of the immune checkpoint inhibitor programmed death ligand-1 and accumulation of T-regulato

223 Responses were achieved regardless of tumor programmed death ligand-1 expression.

224 overall survival (OS) and response by tumor programmed death ligand-1 expression.

225 parate experiments, antibody blockade of the programmed death ligand-1 receptor programmed death rece

226 -CTLA4 mAb therapy but not with anti-PD-1 or programmed death ligand-1.

227 HCII) and promoting the tolerogenic markers, programmed death-ligand (PD-L)1, PD-L2, and the tryptoph

228 To investigate the expression of programmed death-ligand 1 (PD-L1) and immune checkpoints

229 ity of atezolizumab (MPDL3280A), a humanized programmed death-ligand 1 (PD-L1) antibody, in renal cel

230 which is enhanced when combined with an anti-programmed death-ligand 1 (PD-L1) antibody.

231 Durable tumor immunity required programmed death-ligand 1 (PD-L1) blockade in combinatio

232 the factors that influence responsiveness to programmed death-ligand 1 (PD-L1) blockade.

233 Programmed death-ligand 1 (PD-L1) down-modulates various

234 We evaluated the prognostic value of programmed death-ligand 1 (PD-L1) expression in CTCs in

235 overcome the immune suppression mediated by programmed death-ligand 1 (PD-L1) expression on cancer c

236 mize noninvasive immuno-PET imaging of human programmed death-ligand 1 (PD-L1) expression, in a precl

237 bsence of tumor-infiltrating lymphocytes and programmed death-ligand 1 (PD-L1) expression.

238 mor activity of avelumab, a fully human anti-programmed death-ligand 1 (PD-L1) IgG1 antibody, in pati

239 ockade of the programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint augm

240 sis revealed a heterogeneous distribution of programmed death-ligand 1 (PD-L1) in Her2 transgenic mou

241 the role of Toll-like receptor 2 (TLR2) and programmed death-ligand 1 (PD-L1) in regulating alpha-(1

242 We hypothesize the programmed death-ligand 1 (PD-L1) inhibitor, durvalumab,

243 Purpose Expression of programmed death-ligand 1 (PD-L1) is a potential predict

244 Among the ICPs analyzed, expression of programmed death-ligand 1 (PD-L1) on tumor and infiltrat

245 e programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) pathway play an import

246 Combining MEK inhibition with anti-programmed death-ligand 1 (PD-L1) resulted in synergisti

247 n shows miRNA-mediated induced expression of Programmed Death-Ligand 1 (PD-L1) which inhibits T-cell

248 Inhibition of programmed death-ligand 1 (PD-L1) with atezolizumab can

249 ment also markedly reduced the expression of programmed death-ligand 1 (PD-L1), a negative regulator

250 ators programmed cell death protein 1 (PD1), programmed death-ligand 1 (PD-L1), and B and T lymphocyt

251 c stellate cells (HSCs) suppress T cells via programmed death-ligand 1 (PD-L1), but it remains unknow

252 y T cells and blocking its canonical ligand, programmed death-ligand 1 (PD-L1), lengthened the durati

253 Programmed death-ligand 1 (PD-L1), which exerts T cell s

254 ic blockade of the T cell negative regulator programmed death-ligand 1 (PD-L1, also called B7-H1) can

255 Programmed death-ligand 1 (PD-L1; also called B7-H1 or C

256 ce and eradication through the expression of programmed death-ligand 1 (PD-L1; also called CD274 or B

257 on, and improves the therapeutic efficacy of programmed death-ligand 1 (PD-L1; also known as B7-H1) c

258 This study assessed atezolizumab (anti-programmed death-ligand 1 [PD-L1]) as treatment for meta

259 he safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [PD-L1]) versus chemotherapy i

260 Programmed death-ligand 1 expression on tumor cells and

261 ents and Methods Patients were stratified by programmed death-ligand 1 expression, BRAF status, and b

262 protein 4 or programmed cell death protein 1/programmed death-ligand 1 have displayed durable clinica

263 In return, programmed death-ligand 1 interacts with the constitutiv

264 d, Ag administration induces upregulation of programmed death-ligand 1 on dendritic cells in a T cell

265 vels of MC2, but not those of CD80, CD86, or programmed death-ligand 1 or 2, correlated with T cell r

266 Tumor size and programmed death-ligand 1 status were among the baseline

267 mice, which cannot recognize peptidoglycan, programmed death-ligand 1 was undetected.

268 ed the immune tolerance-associated molecule 'programmed death-ligand 1', whereas in NOD1/2 double kno

269 eased expression of immune modulators PD-L1 (programmed death-ligand 1) and CD86 by myeloid DCs (mDCs

270 igh expression levels of the CD274 molecule (programmed death-ligand 1) and programmed cell death 1,

271 7) and the adaptive immune checkpoint PD-L1 (programmed death-ligand 1).

272 the regulatory pathways in T cells, such as programmed death-ligand 1, programmed cell death 1, or t

273 d dendritic cells and enhanced expression of programmed death-ligand 1, whose expression on monocytes

274 IgD and/or IgM expression (67%), and lack of programmed death-ligand 1/ligand 2.

275 Programmed death ligands (PDLs) are immune-regulatory mo

276 S) and hypersensitive response (HR), a rapid programmed death of infected cells.

277 hown to be involved in the accomplishment of programmed death of plant cells is able to hydrolyze a n

278 Programmed death one homolog (PD-1H) is an immunoglobuli

279 neration often occurs independently of known programmed death pathways, but the underlying molecular

280 Upregulation of programmed death (PD) ligand-1 and -2 in neoplastic and

281 h p16 (Ad.E6E7p16) and also encoding an anti-programmed death (PD)-1 Ab.

282 ials targeting not only CTLA-4, but also the programmed death (PD)-1 and B7-H4 pathways in various di

283 at the engagement of the inhibitory receptor programmed death (PD)-1 on HIV-1-specific CD4(+) and CD8

284 e of hypoxia on immune checkpoint receptors (programmed death [PD]-1 and CTLA-4) and their respective

285 ytotoxic T lymphocyte antigen 4 [CTLA-4] and programmed death [PD]-1).

286 The programmed death protein (PD) 1-PD ligand 1/2 pathway an

287 The programmed death protein (PD-1) and its ligand (PD-L1) p

288 mpened the display of the exhaustion markers programmed death receptor 1 (PD-1) and lymphocyte activa

289 activity of pembrolizumab, a humanised anti-programmed death receptor 1 (PD-1) antibody, in patients

290 geting the programmed death ligand 1 (PD-L1)/programmed death receptor 1 (PD-1) immune checkpoint wer

291 lymphocyte-associated protein 4 (CTLA-4) and programmed death receptor 1 (PD-1) were ineffective in c

292 s has been made clinically in inhibiting the programmed death receptor 1 (PD-1)/PD-L1 interaction to

293 expression of the immuno-modulatory molecule programmed death receptor ligand 1 (PD-L1).

294 st, we found no role for regulatory T-cell-, programmed death receptor-, and transforming growth fact

295 de of the programmed death ligand-1 receptor programmed death receptor-1 (PD-1) showed antitumor effe

296 fector phenotype and decreased expression of programmed death receptor-1 (PD-1), in addition to an el

297 mmune checkpoint blockade with antibodies to programmed death receptor-1 (PD-1).

298 Early phase clinical trials targeting the programmed death receptor-1/ligand-1 (PD-1/PD-L1) pathwa

299 The anti-programmed-death-receptor-1 (PD-1) antibody pembrolizuma

300 essor protein ARF sensitizes cancer cells to programmed death through a surprising mechanism: ARF phy